Browse evidence-based analysis of health-related claims and assertions
When Black men in Africa are diagnosed with prostate cancer, their tumors are usually much bigger and more dangerous-looking under the microscope than when Black men in the U.S. are diagnosed.
Descriptive
Having a BRCA1 mutation raises prostate cancer risk, but not as much as having a BRCA2 mutation.
Correlational
Black men in the U.S. get diagnosed with prostate cancer more often than Black men in Africa or the Caribbean, but that might be because doctors in the U.S. test for it more.
When men with BRCA2 mutations get prostate cancer, it’s often more aggressive and shows up earlier in life than in men without the mutation.
Men who inherit a faulty BRCA2 gene are 2 to 4 times more likely to get prostate cancer than men without it.
If people think only men with peeing problems get prostate cancer, then healthy-seeming men won’t get checked—and that’s dangerous because cancer can be silent.
Most people think if you don’t have trouble peeing, you don’t have prostate cancer—but that’s wrong; most early cancers cause no symptoms at all.
A normal PSA reading can be misleading if your prostate is small—doctors do better at spotting cancer by comparing PSA to prostate size.
Quantitative
Prostate cancer grows on the outside of the prostate, while urinary problems come from swelling in the middle—so one doesn’t cause the other.
Mechanistic
Men who wait until they have trouble peeing to get checked for prostate cancer are much more likely to find out their cancer is already spread, compared to men who get tested even if they feel fine.
Most early prostate cancers don’t cause any urinary problems—so if a man has trouble peeing, it’s probably not cancer, and if he has no symptoms at all, he could still have cancer.
After removing the tumors, the man’s urinary problems didn’t get worse, and a year later, the tumors hadn’t come back.
The tumors in this man’s pelvic organs looked like classic benign nerve tumors under the microscope — they had two distinct tissue patterns, stained positive for S100, and showed no signs of cancer.
Even though this man’s PSA level was normal, an MRI scan showed a spot in his prostate that looked like cancer — but it turned out to be a harmless nerve tumor.
Doctors removed a growth near the bladder and took tissue samples from the prostate and seminal vesicle using minimally invasive techniques; the patient recovered well and his urinary symptoms didn’t get worse after one year.
An older man with a known nerve disorder had three unusual growths in his pelvic area that doctors found to be harmless nerve tumors after testing tissue samples.
Germline mutations in BRCA1 and BRCA2 genes confer a significantly elevated risk of developing prostate cancer in men, independent of family history of prostate cancer.
Assertion
Ethnicity is a significant biological determinant of prostate cancer risk, with men of African descent exhibiting approximately double the incidence and earlier age of onset compared to men of European descent.
Hematuria, whether gross or microscopic, is a pathological indicator requiring clinical evaluation due to its association with urological malignancies, including prostate and bladder cancer.
Metastatic prostate cancer involving the vertebral column can cause spinal cord or cauda equina compression, resulting in lower extremity motor weakness, sensory loss, and loss of bladder or bowel sphincter control.
Prostate cancer exhibits a predilection for osteotropic metastasis, resulting in persistent, non-mechanical bone pain that is present at rest and unresponsive to positional changes.
Prostate-specific antigen (PSA) levels in serum serve as a biomarker for prostate tissue abnormality, enabling detection of early-stage prostate cancer in asymptomatic individuals when anatomical obstruction has not yet occurred.
Prostate tumors originating in the peripheral zones of the gland can grow substantially without compressing the urethra, thereby remaining asymptomatic during early stages.
Early-stage prostate cancer frequently presents without symptoms, creating a diagnostic window where detection without clinical signs is critical for curative intervention.